Pharmaron Beijing CoHKSE:03759 +5.43%95 EBITDA Margin % is 12.98% as of Mar. 2026, which is 49% below its 10-year median of 25.27. GuruFocus rates HKSE:03759 with a GF Score™ of 95/100 and a GF Value™ of HK$22.58 (Fairly Valued). The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, Pharmaron Beijing Co ranks better than 78.53% on this metric.
Pharmaron Beijing Co (HKSE:03759) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pharmaron Beijing Co EBITDA Margin % Related Terms
Pharmaron Beijing Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03759 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (HKSE:03759) has a EBITDA Margin % of 12.98% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharmaron Beijing Co and its competitors. This is 49% below median its historical median of 25.27. Over the past decade, Pharmaron Beijing Co's EBITDA Margin % has ranged from 14.84 to 33.48. According to the industry distribution chart, Pharmaron Beijing Co ranks #201 out of 936 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Pharmaron Beijing Co's EBITDA Margin % too high?
Pharmaron Beijing Co's current EBITDA Margin % of 12.98% is 49% below median its 10-year median of 25.27. Over the past 10 years, this metric has ranged from a low of 14.84 to a high of 33.48. Based on the distribution chart, Pharmaron Beijing Co ranks #201 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #201 out of 936 companies for EBITDA Margin %. This places Pharmaron Beijing Co in the top 22% of its industry — outperforming the majority of peers. Historically, Pharmaron Beijing Co's own EBITDA Margin % has ranged from 14.84 to 33.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current EBITDA Margin % is 12.98%, which is 49% below median its own 10-year median of 25.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Fairly Valued. The stock's GF Value™ is HK$22.58, compared to a current price of HK$20.58 — trading 8.9% below its estimated fair value. The current EBITDA Margin % is 12.98%, which is 49% below median its 10-year median of 25.27. Pharmaron Beijing Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current EBITDA Margin % is 12.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be undervalued.
The current stock price of HK$20.58 is trading 8.9% below its estimated GF Value™ of HK$22.58.
GuruFocus considers Pharmaron Beijing Co to be Fairly Valued.
Key valuation signals for HKSE:03759:
EBITDA Margin %: 12.98% (49% below median its 10-year median of 25.27)
GF Value™: HK$22.58 vs. price of HK$20.58 (8.9% below fair value)
No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
95GF Score
Get the complete analysis for HKSE:03759
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03759 has been successfully added to your 
